Skip to Main Content

INCREASED PLATELET DESTRUCTION

Caplacizumab, a bi-specific antibody that targets the A1 domain of von Willebrand factor and prevents vWF interaction with the platelet glycoprotein Ib-IX-V, can reduce the time to platelet count normalization and 30-day mortality.

CONGENITAL DISORDERS OF COAGULATION

While phase 3 clinical trials of gene therapy for hemophilia A and B have to date been restricted to patients 18 years of age and older, the results look extremely promising.

ANTITHROMBOTIC THERAPY

The International Society for Thrombosis and Haemostasis suggests use of specific direct-acting oral anticoagulants for cancer patients with a diagnosis of acute VTE, no drug-drug interactions, and a low risk of bleeding, but suggests use of low-molecular-weight heparin for those with a high risk of bleeding, including patients with luminal GI cancers with an intact primary tumor, and those at risk for bleeding from the genitourinary or GI tract.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.